Rosuvastatin
Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. It is recommended to be used together with dietary changes, exercise, and weight loss. It is taken orally (by mouth).
| Clinical data | |
|---|---|
| Pronunciation | /roʊˈsuːvəstætɪn/ roh-SOO-və-stat-in |
| Trade names | Crestor, others |
| Other names | Rosuvastatin calcium (USAN US) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603033 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Oral (by mouth) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 20% |
| Protein binding | 88% |
| Metabolism | Liver: CYP2C9 (major) and CYP2C19-mediated; ~10% metabolized |
| Metabolites | N-desmethyl rosuvastatin (major; 1/6–1/9 of rosuvastatin activity) |
| Elimination half-life | 19 hours |
| Excretion | Feces (90%) |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI |
|
| ChEMBL |
|
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.216.011 |
| Chemical and physical data | |
| Formula | C22H28FN3O6S |
| Molar mass | 481.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Common side effects include abdominal pain, nausea, headaches, and muscle pains. Serious side effects may include rhabdomyolysis, liver problems, and diabetes. Use during pregnancy may harm the baby. Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol.
Rosuvastatin was patented in 1991, and approved for medical use in the United States in 2003. It is available as a generic medication. In 2021, it was the thirteenth most commonly prescribed medication in the United States, with more than 32 million prescriptions.